This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Langston, A. L Articles by Ralston, S. H Search for Related Content PubMed PubMed Citation Articles by Langston, A. L Articles by Ralston, S. H Social Bookmarking                   What's this?

An integrated approach to consumer representation and involvement in a multicentre randomized controlled trial

Health Services Research Unit, University of Aberdeen, Polwarth Building, Foresterhill, Aberdeen, AB25 2ZD, UK a.langston{at}abdn.ac.uk

Marilyn Mccallum

National Association for the Relief of Paget's Disease, Manchester

Marion K Campbell

Clare Robertson

Health Services Research Unit, University of Aberdeen, Aberdeen, UK

Stuart H Ralston

Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK

Although, consumer involvement in individual studies is often limited, their involvement in guiding health research is generally considered to be beneficial. This paper outlines our experiences of an integrated relationship between the organisers of a clinical trial and a consumer organisation. The PRISM trial is a UK multicentre, randomized controlled trial comparing treatment strategies for Paget's disease of the bone. The National Association for the Relief of Paget's Disease (NARPD) is the only UK support group for sufferers of Paget's disease and has worked closely with the PRISM team from the outset. NARPD involvement is integral to the conduct of the trial and specific roles have included: peer-review; trial steering committee membership; provision of advice to participants, and promotion of the trial amongst Paget's disease patients. The integrated relationship has yielded benefits to both the trial and the consumer organisation. The benefits for the trial have included: recruitment of participants via NARPD contacts; well-informed participants; unsolicited patient advocacy of the trial; and interested and pro-active collaborators. For the NARPD and Paget's disease sufferers, benefits have included: increased awareness of Paget's disease; increased access to relevant health research; increased awareness of the NARPD services; and wider transfer of diagnosis and management knowledge to/from health care professionals. Our experience has shown that an integrated approach between a trial team and a consumer organisation is worthwhile. Adoption of such an approach in other trials may yield significant improvements in recruitment and quality of participant information flow. There are, however, resource implications for both parties.

Clinical Trials, Vol. 2, No. 1, 80-87 (2005)
DOI: 10.1191/1740774505cn065oa


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M J Haddaway, M W J Davie, I W MCCall, and S Howdle Effect of age and gender on the number and distribution of sites in Paget's disease of bone Br. J. Radiol., July 1, 2007; 80(955): 532 - 536. [Abstract] [Full Text] [PDF]

				H. Thornton Participants in research: Contract to run a trial should include patient-researchers in steering groups BMJ, July 9, 2005; 331(7508): 110 - 110. [Full Text]